By Fineline Cube 
China-based Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. announced a strategic partnership with US-headquartered Medicovestor, Inc. to jointly develop next-generation first-in-class chemoimmunotherapy antibody-drug conjugates (ADCs).
Collaboration Details
The partnership leverages Sanyou Bio’s AI-STAL technology and intelligent drug discovery platform alongside Medicovestor’s ADC technologies, including its dimeric antibody platform (ADoBind) and dual-payload targeting system (ADoTope). This collaboration aims to accelerate the development of ADCs for oncology and autoimmune diseases, combining Sanyou Bio’s AI capabilities with Medicovestor’s proprietary technology to enhance efficacy at lower doses and support combination therapies.
Medicovestor’s Technology and Pipeline
Medicovestor’s lead program has reached the IND-enabling stage, with a pancreatic cancer therapy already submitted for FDA Orphan Drug Designation. The company’s technology platforms enable higher efficacy at lower doses, making its ADCs promising candidates for combination therapies.-Fineline Info & Tech